维康药业
(300878)
| 流通市值：23.29亿 | | | 总市值：23.40亿 |
| 流通股本：1.44亿 | | | 总股本：1.45亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 260,159,620.72 | 253,961,470.43 | 324,272,791.58 | 320,581,976.73 |
| 应收票据及应收账款 | 144,595,255.91 | 137,560,582.54 | 250,020,887.98 | 262,381,708.18 |
| 应收账款 | 144,595,255.91 | 137,560,582.54 | 250,020,887.98 | 262,381,708.18 |
| 应收款项融资 | 22,653,936.68 | 28,154,269.28 | 22,741,754.34 | 32,026,319.79 |
| 预付款项 | 3,018,158.36 | 2,772,229.58 | 4,120,496.06 | 7,522,456.86 |
| 其他应收款合计 | 14,868,822.67 | 52,152,930.85 | 54,120,116.88 | 7,530,493.9 |
| 存货 | 137,159,930.93 | 118,324,926.38 | 109,061,969.38 | 135,217,670.19 |
| 其他流动资产 | 23,338,303.81 | 23,555,873.05 | 24,121,865.25 | 18,610,375.29 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 610,794,029.08 | 616,482,282.11 | 788,459,881.47 | 783,871,000.94 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 25,000,000 | 25,000,000 | 25,000,000 | 25,000,000 |
| 投资性房地产 | 22,211,724.55 | 22,363,838 | 8,204,072.07 | 8,332,705.62 |
| 固定资产 | 785,423,030.1 | 791,607,495.03 | 521,847,230.25 | 538,691,154.14 |
| 在建工程 | 61,840,750.9 | 55,098,016.45 | 387,283,238.33 | 346,488,645.41 |
| 使用权资产 | 6,340,241.38 | 6,957,307.42 | 8,034,919.79 | 25,942,117.09 |
| 无形资产 | 33,146,819.18 | 33,591,998.14 | 33,927,183.04 | 35,100,064.1 |
| 商誉 | 10,941,506.32 | 10,965,179.01 | 17,181,211.06 | 27,036,261.71 |
| 长期待摊费用 | 2,732,747.09 | 2,514,604.36 | 2,386,448.03 | 3,998,953.78 |
| 递延所得税资产 | 47,228,931.8 | 54,665,466.64 | 31,213,710.7 | 28,853,966.86 |
| 其他非流动资产 | 32,990,000 | 33,076,852.4 | 11,506,613.9 | 15,115,153.43 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,027,855,751.32 | 1,035,840,757.45 | 1,046,584,627.17 | 1,054,559,022.14 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,638,649,780.4 | 1,652,323,039.56 | 1,835,044,508.64 | 1,838,430,023.08 |
| 流动负债: | | | | |
| 短期借款 | - | 10,008,861.11 | 60,009,868.06 | 60,159,868.06 |
| 应付票据及应付账款 | 87,009,956.1 | 78,853,866.72 | 47,025,050 | 65,174,861.02 |
| 其中：应付票据 | - | 601,825.64 | 6,961,736.98 | 10,363,817.08 |
| 应付账款 | 87,009,956.1 | 78,252,041.08 | 40,063,313.02 | 54,811,043.94 |
| 预收款项 | 138,324.5 | 497,761.97 | 806,298.13 | 122,622.57 |
| 合同负债 | 9,673,708 | 10,681,828.81 | 13,157,283.59 | 14,526,764.5 |
| 应付职工薪酬 | 3,819,477.73 | 8,139,522.56 | 6,234,221.71 | 8,369,604.94 |
| 应交税费 | 14,223,696.25 | 20,349,825.79 | 6,097,600.8 | 3,415,233.26 |
| 其他应付款合计 | 21,210,015.65 | 19,702,778.21 | 15,018,006.57 | 12,457,178.31 |
| 一年内到期的非流动负债 | 90,759,627.83 | 90,759,627.83 | 2,608,601.8 | 9,788,057.44 |
| 其他流动负债 | 1,257,085.94 | 1,387,472.98 | 1,709,928.52 | 1,887,905.1 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 228,091,892 | 240,381,545.98 | 152,666,859.18 | 175,902,095.2 |
| 非流动负债: | | | | |
| 长期借款 | 197,372,877.74 | 186,619,205.86 | 271,999,724.2 | 271,999,724.2 |
| 租赁负债 | 4,313,220.7 | 5,178,925.04 | 5,475,156.7 | 11,806,215.34 |
| 递延收益 | 37,861,115.39 | 38,922,688.25 | 39,984,261.11 | 40,967,334.15 |
| 递延所得税负债 | 7,371,990.81 | 7,395,663.5 | 883,218.53 | 2,111,134.08 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 246,919,204.64 | 238,116,482.65 | 318,342,360.54 | 326,884,407.77 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 475,011,096.64 | 478,498,028.63 | 471,009,219.72 | 502,786,502.97 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 144,790,322 | 144,790,322 | 144,790,322 | 144,790,322 |
| 资本公积 | 680,767,826.97 | 680,767,826.97 | 680,767,826.97 | 680,767,826.97 |
| 减:库存股 | 49,998,351.8 | 49,998,351.8 | 49,998,351.8 | 49,998,351.8 |
| 盈余公积 | 65,194,788.4 | 65,194,788.4 | 65,014,532.55 | 65,014,532.55 |
| 未分配利润 | 307,057,315.8 | 316,911,974.14 | 507,822,621.58 | 477,917,240.91 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,147,811,901.37 | 1,157,666,559.71 | 1,348,396,951.3 | 1,318,491,570.63 |
| 少数股东权益 | 15,826,782.39 | 16,158,451.22 | 15,638,337.62 | 17,151,949.48 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,163,638,683.76 | 1,173,825,010.93 | 1,364,035,288.92 | 1,335,643,520.11 |
| 负债和股东权益合计 | 1,638,649,780.4 | 1,652,323,039.56 | 1,835,044,508.64 | 1,838,430,023.08 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-28 | 2024-08-30 |
| 审计意见(境内) | | 保留意见 | | |